How Cannabis is Already Replacing Opioids for Pain Management
October 15th, 2018
It has long been known medical cannabis helps with pain management. From acute sharp short term pain, to chronic, deeper more long lasting pain, multiple studies have shown cannabis can replace opioids for pain management and help suffering patients live more normal lives.
However, as we know, when it comes to cannabis in the United States, it’s never as straight forward as just going to the doctor and picking up a prescription.
Well, that is slowly changing.
As cannabis becomes more main stream in the US, medical cannabis is replacing opioids for pain management. There are thirty states with medical cannabis programs, more than a handful of states with high CBD cannabis laws and eight states with adult use cannabis, opening Cannabinoid medication access to a record number of Americans.
Nowhere else is cannabis replacing opioids for pain management faster than in Florida.
After passing a full plant medical cannabis law in 2016, Florida pain patients have started choosing cannabis over more addictive deadly opiate medications, says Kim Rivers CEO of Trulieve, Florida’s largest medical cannabis provider. True Leaf operates seventeen dispensaries across the state of Florida, and serves 80,000 registered patients. No one else has their finger on the pulse of Florida medical cannabis more than Kim Rivers.
She tells CNBC in a recent interview, “There have been a number of recent studies that have come out that have shown that in states where medical cannabis programs are robust, the number of opiate prescriptions reduces dramatically. We also know from firsthand true stories, which we have on our website every Tuesday, that a number of our patients are transitioning from opioids to medical cannabis very effectively, and it’s a much safer and effective alternative.”
Kim Rivers goes on to say Trulieve will lobby the Florida legislature to make medical cannabis an easier choice for patients with pain management issues.
The study Kim Rivers speaks of is research published by Jama Internal Medicine, which looked at data from Medicare.
The researchers noticed a fourteen percent reduction in opioid prescriptions in states with easy access to medical cannabis. This, they estimate, adds up to about 3.7 million less doses of opiates a day.
That is a lot of pills!
Another study looked at data from Medicaid and found similar results. Other studies have shown encouraging results with a twenty-five percent decrease in opiate overdoses in states with easy access to medical cannabis.
In addition, baby boomers and seniors are using medical cannabis as replacements for opioids for pain management in record numbers. Seniors and boomers are learning that conditions like osteo-arthritis and other painful geriatric diseases are no match for Cannabinoid medicines, despite the higher cost.
Cannabinoids are the unique compounds found in the cannabis plant. The two most common Cannabinoids cannabidiol (CBD) and Tetrahydrocannabinol (THC) have been shown in multiple studies to be powerful pain relieving compounds. The two compounds work much in the same way by dampening pain receptors throughout the body and reducing inflammation. By attaching to CB1 and CB2 receptors, Cannabinoids can treat pain in different parts of the body.
These receptors make up the endocannabinoid system. The endocannabinoid system is a group of cells that help bring balance to the body. Both compounds were discovered in the 1960’s in Israel, but research into their therapeutic properties has been sparse in the US due to cannabis’ classification as a Schedule One Narcotic, a drug with no known medical use.
For decades patients suffering from pain who wanted to use cannabis had to risk arrest for cannabis possession, or settle for more addictive opioid medications. Now with laws loosening, more and more people are finding medical cannabis can replace opioids for pain management.
Follow Us on Social Media
About CFN Media
CFN Media (CannabisFN) is the leading creative agency and media network dedicated to legal cannabis. We help marijuana businesses attract investors, customers (B2B, B2C), capital, and media visibility. Private and public marijuana companies and brands in the US and Canada rely on CFN Media to grow and succeed.
CFN launched in June of 2013 to initially serve the growing universe of publicly traded marijuana companies across North America. Today, CFN Media is also the digital media choice for the emerging brands in the space.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.